Cagrilintide (5mg) / Tirz (10mg)

Triple-Receptor Agonist: Combines amylin, GIP, and GLP-1 pathways in one formulation
Multi-Pathway Engagement: Three independent satiety and metabolic control mechanisms
Research Blend: 5mg Cagrilintide + 10mg Tirzepatide, ≥98% purity each component

Manufacturer: RiboCore

Availability: In stock

SKU: CAG5-TIRZ10-BLD

Old price: $199.00

Price: $149.00

Ship to

Shipping Method

Estimated Delivery

Price

No shipping options

Technical Specifications

Characteristic	Value
Cagrilintide CAS Number	2224145-04-4
Tirzepatide CAS Number	2023788-19-2
Tirzepatide Molecular Weight	~4,813.5 Da
Purity	≥98% (each component, HPLC)
Form	Lyophilized powder
Total Peptide Content	15 mg (5mg + 10mg)

This novel research blend represents the first triple-receptor agonist combination targeting amylin receptors (via Cagrilintide) plus dual GIP/GLP-1 receptors (via Tirzepatide). Tirzepatide (Mounjaro®, Zepbound®) demonstrated unprecedented 20.9% mean weight loss at 72 weeks in the SURMOUNT-1 trial. The addition of Cagrilintide, a long-acting amylin analog with ~7 day half-life, provides a research tool for investigating whether triple-pathway engagement offers advantages over existing dual-agonist approaches.

Cagrilintide activates AMY1/2/3 receptors in the area postrema, providing meal termination signaling and gastric emptying modulation. Tirzepatide's dual GIP/GLP-1 agonism produces unique "twincretin" effects distinct from single-receptor agonists, with GIP contributing adipose tissue signaling and GLP-1 providing central appetite regulation and cardiovascular protection.

Research Applications

Triple-pathway metabolic signaling research
Comparison of dual vs. triple receptor engagement
Enhanced obesity research models
Comprehensive glucose homeostasis studies
Receptor pharmacology and pathway crosstalk
Body composition analysis with multi-pathway activation